Generic Name: Mellaril
What is Mellaril?
Patients who have had a history of heart disease, high blood pressure, heart disorders including slow heartbeats, have ever had breast cancer, enlarged prostate, liver or kidney complications, seizures, Parkinson's disease, urination problems, low potassium levels or who have had a past serious side effect to any thioridazines or phenothiazines should not take this drug without consulting with a physician first.
Reading the information on this website does not create a physician-patient relationship. West Virginia Wisconsin Wyoming -Puerto Rico- -U. Virgin Islands- -Other- Date you started taking this drug:Date you stopped taking this drug:Please describe side effects: No Yes, I agree to the Parker Waichman LLP disclaimers. Health Canada received reports of three deaths between 2000 and 2005 possibly related to Mellaril, with the most recent death occurring in February 2005.
Because Novartis and other manufacturers failed to make convincing safety information available, Health Canada advised the companies that sales were to end by September 30, 2005. Health Canada recommended that patients who use Mellaril seek advice from their doctors in order to be switched to alternate medications. The warning states that Mellaril, like similar drugs, is associated with deaths. The drug prolongs the QTc interval in a dose related manner.
The letter also stated that Mellaril is only indicated only for those schizophrenic patients who fail to respond to other antipsychotic drugs. Please note that you are not considered a client until you have signed a retainer agreement and your case has been accepted by us. Prior results do not guarantee or predict a similar outcome with respect to any future matter.
If you take 1 dose a day and remember later in the day, take the dose immediately. Side effects cannot be anticipated. If any develop or change in intensity, inform your doctor as soon as possible. Only your doctor can determine if it is safe for you to continue taking Mellaril. Due to the danger of cardiac irregularities, Mellaril must never be combined with drugs that increase its effects or prolong the part of the heartbeat known as the QTc interval.
See "Most important fact about this drug. Do not take Mellaril if you have heart disease accompanied by severe high or low blood pressure. Mellaril may cause tardive dyskinesia--a condition marked by involuntary muscle spasms and twitches in the face and body. Ask your doctor for information about this possible risk. Drugs such as Mellaril are also known to cause a potentially fatal condition known as Neuroleptic Malignant Syndrome. This drug may impair your ability to drive a car or operate potentially dangerous machinery.
Do not participate in any activities that require full alertness until you are certain the drug will not interfere. Remember that combining Mellaril with certain drugs can increase the danger of potentially fatal heartbeat irregularities.
How should I take Mellaril?
The risk or severity of adverse effects can be increased when Thioridazine is combined with Olopatadine. Thioridazine may increase the central nervous system depressant CNS depressant activities of Orphenadrine. The risk or severity of adverse effects can be increased when Thioridazine is combined with Osanetant. The risk or severity of adverse effects can be increased when Thioridazine is combined with Oxazepam.
The risk or severity of adverse effects can be increased when Thioridazine is combined with Oxybuprocaine. The risk or severity of adverse effects can be increased when Paclitaxel is combined with Thioridazine. The risk or severity of adverse effects can be increased when Papaverine is combined with Thioridazine. Thioridazine may increase the central nervous system depressant CNS depressant activities of Paraldehyde.
What should I avoid while taking Mellaril?
However, some patients may require treatment despite the presence of the syndrome. For further information about the description of tardive dyskinesia and its clinical detection, please refer to the sections on Information for Patients and ADVERSE REACTIONS.
It has been suggested in regard to phenothiazines in general, that people who have demonstrated a hypersensitivity reaction e. Attention should be paid to the fact that phenothiazines are capable of potentiating central nervous system depressants e. Physicians should carefully consider benefit versus risk when treating less severe disorders.
Reproductive studies in animals and clinical experience to date have failed to show a teratogenic effect with Mellaril thioridazine hcl.
Mellaril side effects
Thioridazine can cause a life-threatening heart rhythm disorder, especially if you use certain other medicines at the same time. Many medicines should not be taken together with thioridazine, including certain antibiotics, antidepressants, heart or blood pressure medicine, other antipsychotic medicines, and medicines to treat cancer, malaria, HIV or AIDS.
Tell your doctor about all medicines you use, and those you start or stop using during your treatment with thioridazine. Many medicines should not be taken together with thioridazine because they may cause this heart rhythm disorder or other serious medical problems.
This includes:Long-term use of thioridazine can cause a serious movement disorder that may not be reversible.
Common Mellaril ide effects may include:
Autonomic Nervous System -- Dryness of mouth, blurred vision, constipation, nausea, vomiting, diarrhea, nasal stuffiness, and pallor.
Selected from data included with permission and copyrighted by First Databank, Inc.
Visual field testing shows a dose-dependent decrease in retinal sensitivity and may be helpful in detecting toxicity.
You should not use this medication if you are allergic to thioridazine or other anti-psychotic drugs, or if you have untreated or uncontrolled high blood pressure hypertensionvery low blood pressure, a serious heart rhythm disorder, a history of Long QT syndrome, or if you are also using large amounts of alcohol or medicines that make you sleepy.
Based on this data, the following WARNING has been added to the prescribing information: Immune-Mediated Hemolytic Anemia Reports of hemolytic anemia, some serious, diagnosed 4-6 months after the start of RAPTIVA treatment have been received.
RAPTIVA should be discontinued if hemolytic anemia occurs. This information has also been included in the ADVERSE REACTIONS section and Patient Information sheet. The WARNINGS section concerning thrombocytopenia has been relabeled Immune-Mediated Thrombocytopenia and has been updated to include postmarketing reports.
Where can I get more information?
Many drugs can interact with thioridazineand some drugs should not be used together.
It seems to cause far fewer and far less severe extrapyramidal muscle side effects, and it does not seem to cause tardive dyskinesia.